ANTI FUNGAL DRUG CICLOPIROX MAY KILL HIV VIRUS FOR EVER 

PROF.DRRAM ,HIV/AIDS,SEX DIS.,SEX WEAK.& ABORTION EXPERT 
profdrram@gmail.com,+917838059592,+919832025033,DELHI –NCR,IND 
HIV/ AIDS,CANCER LATEST MEDICINES AVAILABLE AT CHEAP RATE. 
FOLLOW ON FACE BOOK:www.facebook.com/ramkumar 
FOLLOW ON TWITTER:www.twitter.com/profdrram

An already approved anti-fungal drug can kill the HIV virus in lab cultures. Since the drug has already been tested on humans, clinical trials maybe around the corner.A topical anti-fungal drug called Ciclopirox causes HIV-infected cells to commit suicide by jamming up the cells' powerhouse, the mitochondria - according to a study by researchers at Rutgers New Jersey Medical School. And unlike current anti-HIV drugs, Ciclopirox completely eradicates infectious HIV from cell cultures, with no rebound of virus when the drug is stopped. The study has been published in the journal PLOS ONE. 

The treatment of patients with HIV has been revolutionised by the advent of combination anti-retroviral drugs. But although these drugs are highly effective at keeping HIV at bay, they must be taken for the life of the patient and never eliminate the infection completely.This is illustrated by the often rapid resurgence of virus in patients who stop taking these medications.The persistence of HIV is partially due to the ability of the virus to disable the cell's altruistic suicide pathway, which is normally activated when a cell becomes infected or damaged. 

A team of researchers from three departments at New Jersey Medical School,Led Zeppelin Officialy Michael Mathews and Hartmut Hanauske-Abel, previously showed that Ciclopirox, commonly used by dermatologists and gynecologists to treat fungal infections, inhibits the expression of HIV genes in culture. 

The group now shows that the drug works against HIV in two ways: It inhibits the expression of HIV genes and also blocks the essential function of the mitochondria, thereby reactivating the cell's suicide pathway.Healthy, uninfected cells examined during this study were spared. And remarkably, the virus did not bounce back when Ciclopirox was removed. 

Indeed, the authors note the speed with which a second FDAapproved drug believed to have promise in subduing HIV, Deferiprone, has moved directly from tests in culture to a phase I human trial conducted in South Africa, thanks to previously published results now reinforced by additional research in culture described in the current paper.In contrast to Ciclopirox, approved for topical use, Deferiprone is approved for systemic use (in certain thalassemia patients with iron overload).
The discovery that two drugs, each well-tolerated by patients when used as indicated, are deadly to HIV-infected cells, may open a new chapter in the fight against HIV/AIDS that moves the world closer to the eradication of HIV-1 infection.